Trial Profile
A phase II, multi center, double-blind, randomized, placebo controlled, dose-escalation, pharmacokinetic and pharmacodynamic study of CK-1827452 in patients with stable heart failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2021
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 19 Aug 2011 Results from this trial have been published in The Lancet, according to a Cytokinetics media release.
- 15 Sep 2009 Results were presented at the 2009 Heart Failure Society of America Annual Meeting in Boston, Massachusetts, according to a Cytokinetics media release.
- 31 Aug 2009 Results were presented at the European Society of Cardiology Congress 2009, according to a Cytokinetics media release.